Troponin I level in risk stratification of non-ST-elevation myocardial infarction in smokers

Authors

  • Iram Shahriar Department of Pharmacology, National Institute of Cardiovascular Diseases, Dhaka
  • Shahina Sobhan Department of Biochemistry, National Institute of Cardiovascular Diseases, Dhaka
  • Ziarrat Islam Department of Cardiology, National Institute of Cardiovascular Diseases, Dhaka

DOI:

https://doi.org/10.3329/bjp.v5i2.6666

Keywords:

Myocardial infarction, Troponin I, Smoker

Abstract

A prospective study was carried out to evaluate the role of troponin I in risk stratification of non-ST-elevation myocardial infarction in 40 smoker and 40 non-smoker patients. The troponin I was significantly higher (p<0.001) in smokers (35.5 ± 5.22 ng/mL) than non-smoker (0.27 ± 0.01 ng/mL). The duration of hospital stay was longer in Group I (106.6 ± 2.36 hour) than in Group II (49.20 ± 1.01 hour). The major adverse cardiac event was higher in smoker (71.79%) compared to non-smokers (10.8%). So, it may be concluded that higher value of troponin I with history of smoking in non-ST-elevation myocardial infarction may be considered as 'high risk group' patients.

Downloads

Download data is not yet available.
Abstract
201
Download
94 Read
3

References

Adams JE, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, Jaffe AS. Cardiac troponin I: A marker with high specificity for cardiac injury. Circulation 1993; 88: 101-06.

Alp NJ, Bell JA, Shahi M. A rapid troponin I based protocol for assessing acute chest pain. QJM. 2001; 94: 687-94.

Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Cardiac-specific troponin I level to predict the risk of mortality in patient with acute coronary syndrome. N Engl J Med. 1996; 335: 1342-49.

Black HR. Smoking and cardiovascular disease. In: Hypertension: Pathophysiology, diagnosis and management. Largh JH, Brenner BM (eds). 2nd edi. New York, Ravan Press Ltd., 1995, pp 2621-47.

Cummins B, Auckland ML, Cummins P. Cardiac-specific troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction. Am Heart J. 1987; 113: 1333-44.

Gardner C, McMillan MD. Development of arteriosclerosis. Am J Cardiol. 1973; 31: 542-46.

Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patient with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med. 1997; 337: 1648-53.

Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R. Clopidogrel used in combination with aspirin compared with aspirin alone in treatment of non-ST-segment-elevation acute coronary syndrome: A systematic review and economic evaluation. Health Technol Assess. 2004; 8: 1-141.

Mayhan WG, Sharpe GM. Effect of cigarette smoke extract on arteriolar dilatation in vivo. J Appl Physiol. 1996; 81: 1996-2003.

Millat MH. Smoking is hazardous to health. The Daily Star. January 2, 2005.

Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndrome: Simultaneous assessment of troponin I, C-reactive protein, B-type natriuretic peptide. Circulation 2002; 105: 1760-63.

Additional Files

Published

2011-01-14

How to Cite

Shahriar, I., S. Sobhan, and Z. Islam. “Troponin I Level in Risk Stratification of Non-ST-Elevation Myocardial Infarction in Smokers”. Bangladesh Journal of Pharmacology, vol. 5, no. 2, Jan. 2011, pp. 82-84, doi:10.3329/bjp.v5i2.6666.

Issue

Section

Research Articles